Fred Hutch Cell Therapy Lab

Seattle, WA
National Center
CAR-T Cell Therapy
No confirmed program data — ClinicalTrials.gov verification pending · Last scored 2026-09-07
76.3
Signal Score
○ FDA Inspections ✓ Clinical Trials (535) ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Fred Hutch Cell Therapy Lab

Signal Score
76.3/100 (as of 2026-09-07)
Quality Compliance
Assessment pending
Headquarters
Seattle, WA
Modalities
CAR-T, Cell Therapy
Active Programs
Data pending
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Fred Hutch Cell Therapy Lab

CDMO.

Signal Score & Pillar Breakdown

Scores are being republished. Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
Operations 97.7
Programs — no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
NCT04579523 ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With... PHASE1 Not Yet Recruiting
NCT07774104 A Structured Peer Support Intervention for Patients... NA Not Yet Recruiting
NCT07803653 IL-18 Armored STEAP1 CAR T Cells for the Treatment of... PHASE1 Not Yet Recruiting
NCT05621291 A Multicenter Study to Evaluate Next-Generation Sequencing... NA Recruiting
NCT07648264 Single-arm Study of IgPro20 in Adults With Secondary Immune... PHASE3 Recruiting
NCT07194980 Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment... PHASE2 Recruiting
NCT07645469 FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of... PHASE1 Recruiting
NCT07225985 Pralatrexate With Bendamustine and Total-Body Irradiation... PHASE1/PHASE2 Recruiting
NCT07228624 Ruxolitinib Before, During and After Hematopoietic Cell... PHASE2 Recruiting
NCT06983899 Exercise Training for the Improvement of Immune Activity and... NA Recruiting
View all 535 programs →
Source: ClinicalTrials.gov · Retrieved Oct 07, 2026
Financial Stability 68.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity 58.0
Profile-based capacity assessment

Clinical Activity 535 studies

NCT04579523 ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With... PHASE1 Not Yet Recruiting NCT07774104 A Structured Peer Support Intervention for Patients Undergoing Hematopoietic... NA Not Yet Recruiting NCT07803653 IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration... PHASE1 Not Yet Recruiting NCT05621291 A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and... NA Recruiting NCT07648264 Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due... PHASE3 Recruiting NCT07194980 Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of... PHASE2 Recruiting NCT07645469 FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal... PHASE1 Recruiting NCT07225985 Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor... PHASE1/PHASE2 Recruiting NCT07228624 Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older... PHASE2 Recruiting NCT06983899 Exercise Training for the Improvement of Immune Activity and Treatment... NA Recruiting NCT07227571 Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of... PHASE1 Recruiting NCT07098364 ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in... PHASE1/PHASE2 Recruiting NCT06817889 Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV... PHASE2 Recruiting NCT07225946 A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With... PHASE3 Recruiting NCT06947928 Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In... PHASE2/PHASE3 Recruiting NCT07222267 An Investigational Study of BG-75202 Alone and in Combination With Other... PHASE1 Recruiting NCT07052630 Patient Navigation and the Planning Advance Care Together Website to Improve... NA Recruiting NCT07006727 Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing... PHASE1 Recruiting NCT07046078 Combination Chemotherapy (FLAG-Ida) Followed Immediately by... PHASE2 Recruiting NCT06752694 Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After... PHASE2 Active Not Recruiting
+ 515 more studies
Source: ClinicalTrials.gov · Retrieved Oct 07, 2026

Frequently Asked Questions About Fred Hutch Cell Therapy Lab

How many clinical programs is Fred Hutch Cell Therapy Lab linked to?
Fred Hutch Cell Therapy Lab is associated with 535 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Fred Hutch Cell Therapy Lab's CDMO Signal Score?
Fred Hutch Cell Therapy Lab has a Signal Score of 76/100, based on quality, operations, financial stability, and capacity data.
Evaluating Fred Hutch Cell Therapy Lab for a manufacturing program?
Use the free AI matchmaker to compare Fred Hutch Cell Therapy Lab against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 91.1
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 90.9
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 83.9
CAR-T, Cell Therapy
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.3
CAR-T, Cell Therapy
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 82.9
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody